@article{21c869c3e730408caa79ff8001240245,
title = "Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis",
keywords = "multiple sclerosis",
author = "Nevin John and Antonia Carroll and Brownlee, {Wallace J.} and Jeremy Chataway",
note = "Funding Information: competing interests WJB has received speaker honoraria for educational activities for Merck serono, roche and sanofi Genzyme. JC has received support from the efficacy and Mechanism evaluation Programme and Health technology Assessment Programme (NIHr); UK Multiple sclerosis society and National Multiple sclerosis society; National Institute for Health research University College London Hospitals (NIHr-UCLH) Biomedical research Centre (BrC) and University College London. In the last three years, he has been a local principal investigator for trials in multiple sclerosis funded by: receptos, Novartis and Biogen Idec, and has received an investigator grant from Novartis outside this work. He has taken part in Advisory Boards/consultancy for Apitope, roche, Merck, MedDay, Biogen and Celgene.",
year = "2019",
month = dec,
doi = "10.1136/jnnp-2019-320687",
language = "English",
volume = "90",
pages = "1376--1378",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ",
number = "12",
}
